EQL Pharma shareholders voted to carry forward 2025/26 earnings, no dividend paid

• EQL Pharma held its annual general meeting on Aug. 20, 2026, adopting the FY 2025/2026 parent and consolidated financial statements.
• Shareholder distribution proposal was endorsed; no dividend will be paid for FY 2025/2026, with available funds carried forward.
• Liability discharge for the board members and CEO for FY 2025/2026 was granted.
• Board and committee fee framework was set, including SEK 450,000 for the chair, SEK 250,000 for other non-employee directors.
• Long-term incentive program was adopted: up to 100,000 warrants for the Chief Supply Chain Officer, potentially issuing 100,000 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQL Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260819:BIT:9728:0) on August 20, 2026, and is solely responsible for the information contained therein.